Bayer (BAYRY) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the label extension for Eylea 8 mg (aflibercept) in the EU.This extension will enable longer treatment intervals, up to six months, for two major retinal conditions, neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME), pending approval by the European Commission.A decision is anticipated in the coming ...

Company Overview - Kalaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing treatments for prevalent retinal diseases [3] - The company is currently developing TH103, a novel anti-VEGF investigational therapy designed to improve VEGF inhibition and retention in the retina [3] Product Development - TH103 is a fully humanized, recombinant fusion protein that acts as a decoy receptor against VEGF [3] - The therapy is currently undergoing a Phase 1 clinical trial for the treatment of neovascular Age-related Macular Degeneration (nAMD) [3] - Kalaris plans to expand the development of TH103 to treat additional retinal diseases, including Diabetic Macular Edema (DME) and Retinal Vein Occlusion (RVO) [3] Upcoming Events - Kalaris management will participate in a Fireside Chat at the Stifel 2025 Virtual Ophthalmology Forum on May 27, 2025 [1][4] - The event will feature speakers Andrew Oxtoby, CEO, and Matthew Feinsod, CMO [4] - A replay of the event will be available on Kalaris Therapeutics' Investor Relations webpage following the event [2]